Terms: = Prostate cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Diagnosis
134 results:
1. Predictive and prognostic biomarkers in urological tumours.
Cimadamore A; Franzese C; Di Loreto C; Blanca A; Lopez-Beltran A; Crestani A; Giannarini G; Tan PH; Carneiro BA; El-Deiry WS; Montironi R; Cheng L
Pathology; 2024 Mar; 56(2):228-238. PubMed ID: 38199927
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence of germline brca1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.
Maekawa S; Takata R; Sekiguchi K; Kagabu M; Toyoshima M; Tamada S; Takahashi K; Ikarashi D; Matsuura T; Kato R; Kato Y; Kanehira M; Sugimura J; Abe T; Baba T; Obara W
Jpn J Clin Oncol; 2024 Apr; 54(4):489-497. PubMed ID: 38157885
[TBL] [Abstract] [Full Text] [Related]
3. Review of the Developing Landscape of prostate Biopsy and Its Roles in prostate cancer diagnosis and Treatment.
Okubo Y; Sato S; Terao H; Yamamoto Y; Suzuki A; Hasegawa C; Yoshioka E; Ono K; Washimi K; Yokose T; Nakaigawa N; Kishida T; Miyagi Y
Arch Esp Urol; 2023 Nov; 76(9):633-642. PubMed ID: 38053418
[TBL] [Abstract] [Full Text] [Related]
4. A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score.
Chen Z; Zhang J; Jin D; Wei X; Qiu F; Wang X; Zhao X; Pu J; Hou J; Huang Y; Huang C
BMC Cancer; 2023 Nov; 23(1):1138. PubMed ID: 37996859
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive causes of death in uveal melanoma: mortality in 1530 consecutively diagnosed patients followed until death.
Stålhammar G
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37972025
[TBL] [Abstract] [Full Text] [Related]
6. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
7. Pretest Video Education Versus Genetic Counseling for Patients With prostate cancer: ProGen, A Multisite Randomized Controlled Trial.
Rana HQ; Stopfer JE; Weitz M; Kipnis L; Koeller DR; Culver S; Mercado J; Gelman RS; Underhill-Blazey M; McGregor BA; Sweeney CJ; Petrucelli N; Kokenakes C; Pirzadeh-Miller S; Reys B; Frazier A; Knechtl A; Fateh S; Vatnick DR; Silver R; Kilbridge KE; Pomerantz MM; Wei XX; Choudhury AD; Sonpavde GP; Kozyreva O; Lathan C; Horton C; Dolinsky JS; Heath EI; Ross TS; Courtney KD; Garber JE; Taplin ME
JCO Oncol Pract; 2023 Nov; 19(11):1069-1079. PubMed ID: 37733980
[TBL] [Abstract] [Full Text] [Related]
8. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
Tseng CH
Front Endocrinol (Lausanne); 2023; 14():1185053. PubMed ID: 37560306
[TBL] [Abstract] [Full Text] [Related]
9. Biallelic
Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
[TBL] [Abstract] [Full Text] [Related]
10. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
11. Hereditary breast and ovarian cancer: from genes to molecular targeted therapies.
Ponti G; De Angelis C; Ponti R; Pongetti L; Losi L; Sticchi A; Tomasi A; Ozben T
Crit Rev Clin Lab Sci; 2023 Dec; 60(8):640-650. PubMed ID: 37455374
[TBL] [Abstract] [Full Text] [Related]
12. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
13. [The value of DISCO and MUSE-DWI combined with prostate specific antigen density in the diagnosis and risk stratification of prostate cancer].
Chen ZQ; Zhang D; Wang Z; Song N; Ma AL; Zhang SR; Cai L
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1461-1468. PubMed ID: 37198108
[No Abstract] [Full Text] [Related]
14. Health Care Costs Attributable to prostate cancer in British Columbia, Canada: A Population-Based Cohort Study.
Zhang W; Guh DP; Mohammadi T; Pataky RE; Tam ACT; Lynd LD; Conklin AI
Curr Oncol; 2023 Mar; 30(3):3176-3188. PubMed ID: 36975453
[TBL] [Abstract] [Full Text] [Related]
15. Molecular characteristics of Asian male BRCA-related cancers.
Kwong A; Ho CYS; Shin VY; Ng ATL; Chan TL; Ma ESK
Breast Cancer Res Treat; 2023 Apr; 198(2):391-400. PubMed ID: 36637704
[TBL] [Abstract] [Full Text] [Related]
16. prostate cancer risk, screening and management in patients with germline brca1/2 mutations.
Rajwa P; Quhal F; Pradere B; Gandaglia G; Ploussard G; Leapman MS; Gore JL; Paradysz A; Tilki D; Merseburger AS; Morgan TM; Briganti A; Palapattu GS; Shariat SF
Nat Rev Urol; 2023 Apr; 20(4):205-216. PubMed ID: 36600087
[TBL] [Abstract] [Full Text] [Related]
17. Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline brca1 mutation: a case report.
Liu Y; Zhu J; Wei X; Yang D; Li S; Qian X; Li L
J Ovarian Res; 2022 Dec; 15(1):127. PubMed ID: 36463302
[TBL] [Abstract] [Full Text] [Related]
18. Germline Variants in DNA Damage Repair Genes and
Trendowski MR; Sample C; Baird T; Sadeghpour A; Moon D; Ruterbusch JJ; Beebe-Dimmer JL; Cooney KA
JCO Precis Oncol; 2022 Nov; 6():e2200460. PubMed ID: 36446039
[TBL] [Abstract] [Full Text] [Related]
19. [Importance of genetic testing in prostate cancer].
Steinkellner L; Luger F; Loidl W
Urologie; 2022 Dec; 61(12):1392-1398. PubMed ID: 36378280
[TBL] [Abstract] [Full Text] [Related]
20. Characteristics of BRCA2 Mutated prostate cancer at Presentation.
Han H; Park CK; Cho NH; Lee J; Jang WS; Ham WS; Choi YD; Cho KS
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362213
[TBL] [Abstract] [Full Text] [Related]
[Next]
